In contrast, the combination of the anti-PD-L1 agent atezolizumab and the anti-vascular endothelial growth factor monoclonal antibody bevacizumab has demonstrated a significant improvement in overall survival (OS) compared to the previous standard of care, sorafenib, leading to its approval as a first-line systemic treatment for patients with unresectable HCC [6]. Here, CD274 is linked to hepatocellular carcinoma.